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Abstract
Background: Data on Chronic Myeloid Leukemia (CML) prevalence are scarce. 
Here we provide an estimation of the prevalence of CML in France for the year 2014 
using French national health insurance data.
Methods: We selected patients claiming reimbursement for tyrosine kinase in-
hibitors (TKI) or with hospital discharge diagnoses for CML, BCR/ABL‐positive 
or with full reimbursement of health care expenses for myeloid leukemia. We 
built an algorithm which we validated on a random sample of 100 potential CML 
patients by comparing the results obtained using the algorithm and the opinion of 
two hematologists who reviewed the patient demographics and sequence of care 
abstracted from claims data (internal validity). For external validity, we compared 
the number of incident CML patients identified using the algorithm with those 
recorded in French population‐based cancer registries in departments covered by 
such a registry.
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1 |  INTRODUCTION
Chronic Myeloid Leukemia (CML) is a myeloproliferative 
neoplasm whose age‐adjusted annual incidence rate is around 
1 per 100 000 person‐years in European countries.1,2 Since 
the introduction of tyrosine kinase inhibitors (TKI) in the 
early 2000s, the survival of patients with CML has improved 
dramatically.3-7 As CML incidence increases with age, an 
aging population combined with an improvement in survival 
is expected to increase CML prevalence. Based on the esti-
mations from 22 cancer registries in Europe, the prevalence 
of CML was estimated to be 5.6 per 100 000 in 2008.8 In 
Sweden, CML prevalence was estimated at 5.7 per 100 000 in 
2000 and 11 per 100 000 in 2012.4,9 In the United States, the 
number of CML cases was estimated to be 70 000 in 2010, 
indicating a high prevalence of 22.6 per 100 000 inhabitants, 
with a predicted number of cases reaching 112 000 in 2020.10 
In France, a regional hospital‐based evaluation of CML prev-
alence (Nord‐Pas de Calais region) indicated an increase in 
CML prevalence from 5.8 to 10.4 per 100  000 inhabitants 
between 1998 and 2007.11 In France, CML prevalence was 
recently modeled from 1960 to 2060 by using incidence rates 
from six French population‐based cancer registries (corre-
sponding to 11 departments and covering 14% of the French 
population). Scenarios combining projections of the French 
population and various hypotheses on the evolution of rela-
tive survival of CML patients were proposed. In the base case 
scenario, CML prevalence was estimated at 2.5 per 100 000 
inhabitants before the 1980s, 6.4 in 2002, 13.7 in 2012, and 
17.5 in 2018, with an anticipated plateau at 32 per 100 000 
inhabitants in the 2060s.12 These estimates of CML preva-
lence were obtained through a modeling exercise using data 
on relative survival from other European countries. Modeling 
estimates of CML prevalence were consistent with the num-
ber of imatinib sales in 2004 and the regional estimate of 
CML prevalence in Nord‐Pas de Calais until 2007. But since 
then, no recent data were available to validate modeling 
estimates.
Administrative healthcare databases are regularly used 
to assess the economic burden of diseases and to allocate 
resources both at the national and the regional level. More 
recently, these data sources have been extensively used in 
economic evaluation to estimate input parameters in cost‐ef-
fectiveness studies. Similarly, administrative and claims data 
are used to estimate target populations and market shares 
for pricing and reimbursement of new medicines as well as 
postmarketing surveillance studies. In addition, administra-
tive databases are relevant sources of data to conduct epide-
miological studies worldwide.13-18 In the present study, our 
objective was to build and validate an algorithm to assess the 
prevalence of CML at the nationwide level, using individual 
data from French national insurance databases. Our aim was 
also to make available an algorithm to identify CML patients 
in administrative healthcare databases that could be used for 
future economic evaluations or pharmaco‐epidemiological 
studies in this patient population.
2 |  PATIENTS AND METHODS
2.1 | Study design and data sources
We performed a cross‐sectional study using data from the 
French national health insurance database linked with the 
national hospital discharge database.19-21 These databases 
Results: We identified 10 789 prevalent CML patients in 2014, corresponding to a 
crude prevalence rate of 16.3 per 100 000 inhabitants [95% confidence interval (CI) 
16.0‐16.6]: 18.5 in men [18.0‐19.0] and 14.2 in women [13.8‐14.6]. The crude CML 
prevalence was less than 1.6 per 100  000 [1.2‐2.0] under age 20, increasing to a 
maximum of 48.2 [45.4‐51.2) at ages 75‐79. It varied from 10.2 to 23.8 per 100 000 
across French departments. The algorithm showed high internal and external valid-
ity. Concordance rate between the algorithm and the hematologists was 96%, and the 
numbers of incident CML patients identified using the algorithm and the registries 
were 162 and 150, respectively.
Conclusion: We built and validated an algorithm to identify CML patients in ad-
ministrative healthcare databases. In addition to prevalence estimation, the algorithm 
could be used for future economic evaluations or pharmaco‐epidemiological studies 
in this population.
K E Y W O R D S
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contain individualized, anonymous, and comprehensive data 
on all healthcare reimbursements (including hospital stays 
coded with the International Classification of Diseases, 10th 
Revision (ICD‐10) diagnosis codes, medications, general 
practitioner and specialist consultations, imaging and biolog-
ical procedures and sick/disability leaves) and patient eligi-
bility for full reimbursement of health care expenses related 
to specific costly or long‐term diseases (LTD) also coded 
with ICD‐10 codes. Claims data are gathered across nearly 
all French Health Insurance schemes, covering 98.8% of the 
population living in France (66.4 million inhabitants on 1 
January 2015). Besides healthcare reimbursement data, de-
mographic data are also available including the year of birth, 
gender, area of residence, and date of death. There was no 
requirement for ethics approval to be sought for this obser-
vational study, based on anonymous healthcare claims data.
2.2 | Algorithm to identify CML patients
2.2.1 | Selection of potential CML patients
For the 2006‐2014 period, we selected from the French na-
tional health insurance databases: (a) all patients treated by 
TKI indicated in CML (imatinib, dasatinib, nilotinib, bosu-
tinib or ponatinib) and/or (b) identified by the ICD‐10 di-
agnosis code C92.1 (Chronic Myeloid Leukemia, BCR/
ABL‐positive) among hospital discharge diagnoses and/or 
(c) having requested full reimbursement of health care ex-
penses for Myeloid Leukemia (ICD‐10 diagnosis code C92). 
The latter criterion (ICD‐10 diagnosis code C92 for Myeloid 
Leukemia) is coded only with three characters in the French 
national health insurance databases. It is therefore not spe-
cific for Chronic Myeloid Leukemia and patients with a very 
different disease such as Acute Myeloid Leukemia could also 
be selected using this ICD‐10 code. However, at the time of 
the data extraction, we preferred not to be too restrictive in 
our selection criteria. Then, to refine this selection, we ex-
amined the sequence of care between 2006 and 2014 for 200 
randomly selected individuals, using a standardized form 
(Figure S1). For each individual, this form presented demo-
graphic data and healthcare resource utilization.
2.2.2 | Algorithm building
Based on this thorough examination and clinical opinions, 
we built a claim‐based algorithm to identify CML patients. 
Case definition was based on (a) identifying any TKI reim-
bursement associated with a hospitalization for CML or last-
ing ≥2 months and (b) excluding patients receiving TKIs for 
diseases other than CML including Philadelphia positive Acute 
Lymphoblastic Leukemia, Gastrointestinal Stromal Tumor, 
Graft versus Host Disease, Hyper Eosinophilic Syndrome and 
Stromal or other Connective Tissue Tumor. These differential 
diagnoses were identified using discharge diagnoses, Long‐
Term Disease diagnoses and reimbursement of specific drugs 
(Figure S2). The SAS program of the algorithm is available 
upon request from the corresponding author.
2.3 | CML prevalence
Prevalent CML cases were those identified using the algo-
rithm described above, having at least one healthcare reim-
bursement during the year 2014 and still alive on 31 December 
2014. The nationwide crude CML prevalence rate was defined 
as the number of prevalent CML patients divided by the num-
ber of people living in France on 1 January 2015 (www.insee.
fr) 22 and is provided with an exact Clopper‐Pearson confi-
dence interval.23 The national CML prevalence rate was also 
standardized by gender and by 5‐year age group to the 1976 
European population, and the 1960 World population, to allow 
for international comparisons.24 Both crude and standardized 
rates correspond to estimates of the complete prevalence of 
CML. Crude and standardized prevalence rates by depart-
ment, using the department of residence of prevalent CML 
patients in 2014, were computed to explore geographical vari-
ations in CML prevalence in the French territory. The refer-
ence population for the standardization on gender and age was 
the general population residing in France on 1 January 2015.
2.4 | Algorithm validity
The internal validity of our algorithm was assessed from 
another random sample of 100 potential CML patients. We 
calculated the proportion of agreement between the result of 
the algorithm and the opinion of two expert hematologists 
from the FiLMC group. For each individual, hematologists 
reviewed the standardized patient form presenting patient de-
mographics and sequence of care from claims data.
In addition, we performed an external validation of our 
algorithm using data from French cancer registries. We 
compared the number of incident CML cases (ie new CML 
cases) identified from the French national health insurance 
databases for 3 years from 2012 to 2014 with the number of 
incident CML cases (ICD‐O‐3 9875/3: Chronic myelogenous 
leukemia, BCR/ABL‐positive) recorded in 18 French popu-
lation‐based cancer registries for the same years and the same 
geographical areas (covering 22% of the French population). 
In the French national health insurance databases, the index 
date for the diagnosis of CML was defined as the first date 
among the first date of TKI or hydroxycarbamide reimburse-
ment, or the start date for full reimbursement of health care 
expenses for myeloid leukemia or the first date of hospitaliza-
tion for CML. In a sensitivity analysis, the CML prevalence 
rate was adjusted using the results of external validation (cf. 
Supplementary). Statistical analyses were performed using 
SAS 9.3.
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3 |  RESULTS
3.1 | Population study
68  067 individuals were selected from the French national 
health insurance databases using the selection criteria de-
scribed in the methods section (paragraph 2.2.1). Applying 
the algorithm (paragraph 2.2.2) resulted in the identification of 
10 789 patients with CML on 31 December 2014 (Figure 1). 
Forty‐eight percent of these prevalent CML cases had the three 
selection criteria (TKI, hospitalization with a CML diagnosis 
code, full reimbursement of health care expenses for myeloid 
leukemia), 32% were treated by TKI and benefited from full re-
imbursement of health care expenses for myeloid leukemia, 9% 
had TKI and hospitalization with CML diagnosis code. Finally, 
11% of the CML patients identified using the algorithm were 
captured by TKI reimbursement only. The median age [inter-
quartile range] of the prevalent population of CML patients 
was 63 [51‐73], with a slight male preponderance (55%).
3.2 | Estimation of CML prevalence
On 31 December 2014, the crude prevalence of CML was 
estimated at 16.3 per 100  000 inhabitants in France [95% 
confidence interval (CI) 16.0‐16.6]. The crude prevalence of 
CML was 18.5 per 100 000 in men [95% CI 18.0‐19.0] and 
14.2 per 100,000 in women [95% CI 13.8‐14.6]. To allow 
for international comparisons, standardized prevalence rates 
are shown in Table 1. CML prevalence increased with age 
(Figure 2 and Table S2). The crude prevalence of CML was 
less than 1.6 per 100 000 [95% CI 1.2‐2.0] before 20, progres-
sively increased to 19.4 [95% CI 18.1‐20.8] at 50‐54 years 
and reached a peak of 48.2 [95% CI 45.4‐51.2] at 75‐79 years. 
There was a preponderance of CML in men in all age groups 
except in younger age groups where prevalence was compa-
rable between genders. The crude prevalence of CML varied 
from 10.2 to 23.8 per 100 000 inhabitants across all French 
departments (Figure 3). These variations of prevalence 
F I G U R E  1  Patient flow chart. Data were extracted from the French national health insurance databases for the period 2006‐2014. TKI: 
Tyrosine Kinase Inhibitor, CML: Chronic Myeloid Leukemia
68 067 individuals selected by: TKI reimbursement OR 
Hospitalization for CML OR a Long Term Disease code 
for Myeloid Leukemia between 2006-2014
No TKI reimbursement between 2006-2014 (n = 46 760)
Gastro-intestinal Stromal Tumor (n = 4 736)
Acute Lymphoblastic Leukemia Phi+ (n = 1 458)
Imatinib given for Graft Versus Host Disease (n = 226)
Hyper Eosinophilic Syndrom (n = 204)
Stromal or other connective tissue tumor (n = 643)
Less than 2 months of TKI reimbursement and no hospitalization for CML 
(n = 460)
Patients identified as having CML between 2006-2014 
(n = 13 580)
Patients deceased before December, 31st 2014 (n = 2 106)
Patients without any healthcare reimbursement (drugs, medical or 
paramedical consultations, hospitalization…) for the year 2014 (n = 685)
Prevalent patients with CML on December, 31st 2014 
(n = 10 789)
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persisted to a lesser extent after standardization on gender and 
age (Table S1).
3.3 | Algorithm validation to identify 
CML patients
The comparison of the algorithm with the opinion of he-
matologists indicated a 96% concordance rate (N  =  100). 
According to the hematologists, the algorithm correctly iden-
tified 45 true CML patients and correctly excluded 51 false 
CML patients. However, the algorithm missed three patients 
who had less than 2 months of TKI reimbursement but were 
considered as CML patients by the hematologists, based on 
their sequence of care. Finally, the algorithm selected one 
false positive CML patient. This was a patient with reim-
bursement of imatinib for a short time period and missing 
data for both hospitalization and eligibility status to full re-
imbursement of health care expenses for myeloid leukemia.
For the year 2014, the 18 population‐based cancer regis-
tries from the Francim network identified 150 incident CML 
patients whereas the algorithm identified 162 new CML 
patients for the same areas. The median age [interquartile 
range] of the incident population of CML patients identified 
using the algorithm was 60 [46‐71], with a slight male pre-
ponderance (57%). Considering the cancer registries as the 
gold standard, the algorithm overestimated the number of 
incident CML patients by 8% in 2014 compared to cancer 
registries. In 2013 and 2012, the algorithm overestimated 
the number of incident CML patients by 13% and 14% re-
spectively. In a sensitivity analysis, we provide estimates 
adjusted using the results of the external validation. The ad-
justed crude CML prevalence rate was estimated at 15.1 per 
  Overall Men Women
Number of prevalent CML 
patients on 31 December 2014
10 789 5931 4858
French population in 2014 66 226 643 32 076 965 34 149 678
Crude prevalence of CML per 
100 000 inhabitants
16.3 [16.0‐16.6] 18.5 [18.0‐19.0] 14.2 [13.8‐14.6]
Standardized prevalence rates 
per 100 000 (1960‐World 
population)
10.0 [9.8‐10.3] 11.7 [11.4‐12.0] 8.4 [8.1‐8.6]
Standardized prevalence rates 
per 100 000 (1976‐European 
population)
13.3 [13.1‐13.6] 15.6 [15.2‐16.0] 11.1 [10.8‐11.4]
Abbreviation: CML: Chronic Myeloid Leukemia.
T A B L E  1  Crude and standardized 
prevalence rates of CML in France, in 2014
F I G U R E  2  Age‐specific and gender‐
specific crude CML prevalence rates in 
France in 2014. This figure represents the 
CML crude prevalence rate by age and sex 
of the population prevalent on 31 December 
2014
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100 000 [95% CI 14.8‐15.4] in 2014:17.1 per 100 000 in men 
[95% CI 16.7‐17.6] and 13.2 per 100 000 in women [95% CI 
12.8‐13.5].
4 |  DISCUSSION
Based on the French national health insurance databases, we 
estimated that the crude prevalence of CML in France was 
16.3 per 100 000 inhabitants in 2014. The male preponder-
ance, reported in incidence studies,2,8,25,26 persisted when 
studying prevalence and was constant across the ages, except 
in younger age groups where prevalence was comparable be-
tween genders.
Using different sources of data and methodology, our 
results are consistent with the estimates from Delord et al 
which ranged from 13.7 per 100 000 inhabitants in 2012 to 
17.5 in 2018.12 CML prevalence estimated by Delord et al 
was obtained from projections of the French population, 
incidence rates from six French population‐based cancer 
registries studies and hypotheses on the relative survival 
of CML patients, while we used individual data from the 
French national health insurance databases. Our results in 
2014 are also consistent with the rising trend in the CML 
prevalence estimated by Corm et al in the French region 
Nord‐Pas de Calais, from 5.8 per 100  000 inhabitants in 
1997 to 10.4 in 2007.11 Our CML prevalence estimate of 
16.3 per 100 000 inhabitants in France in 2014 is between 
the Swedish estimate (11 per 100 000 inhabitants in 2012 
and 14 per 100 000 in 2018)4,9 and the US prevalence es-
timates (22.6 per 100 000 in 2010 and 33.5 per 100 000 in 
2020).10 These differences may reflect discrepancies in age 
distribution, leading to different incidence of CML but also 
differences in access to TKI with an impact on survival, 
and differences in methods. It is worth noting that the dif-
ference in CML prevalence between Sweden and United 
States is mainly related to quite different incidence rates 
(0.90 per 100 000 in Sweden and 1.75 per 100 000 in the 
United States), which may be due to a wider definition of 
CML used in the US SEER register or to real differences 
between the two countries. The increase in CML preva-
lence may lead physicians to modify their practices in order 
to care for an increasing number of patients and consider 
new modalities of follow‐up such as clinical routine assess-
ment by clinical nurses. Physicians will also have to adapt 
to the aging of this population, with a peak of prevalence 
at 75‐79 years in our study, as elderly patients may be more 
sensitive to side effects of second generation TKIs.
There were variations in CML prevalence across the 
French territory, which cannot be only explained by differ-
ences in age and gender distribution of the population in the 
French departments (cf. crude and standardized CML prev-
alence by department Table S1). Data presented here corre-
spond to the distribution of the prevalent CML patients in 
the departments in which they lived in 2014. These varia-
tions are unlikely to be explained by a different quality of 
data reporting across the departments because information 
on reimbursement of TKI, on which the algorithm mainly 
relies, is collected the same way across the French territory. 
Data regarding environmental exposures are not available in 
the National Health Insurance databases, precluding associa-
tion studies using individual data for exposure and outcomes. 
However, our finding opens research prospects for geograph-
ical and ecologic studies.
The French national health insurance databases used in 
the present study have several advantages: (a) data are col-
lected prospectively and are readily available to be analyzed, 
(b) the databases cover 98.8% of French population, hence 
avoiding selection bias and providing a large sample size, 
(c) data are available from 2006 onwards with no losses to 
follow‐up. A key issue in studies using healthcare adminis-
trative databases is to develop and validate an algorithm that 
identifies patients with the highest accuracy. Different initia-
tives exist worldwide to encourage the building, validation 
and use of these algorithms, such as the review of algorithms 
used to detect various outcomes of interest within the Mini‐
Sentinel program in the US,27 and the REDSIAM network in 
France.28 Building such algorithms requires expertise in both 
the studied disease and the administrative databases used.
F I G U R E  3  CML prevalence rates in 2014 by Department in 
France. CML: Chronic Myeloid Leukemia. These are crude estimates 
of CML prevalence per 100 000 inhabitants. Departments are those in 
which prevalent CML patients lived in 2014
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The analysis of the sequence of care of 200 randomly 
selected individuals by two expert hematologists using a 
standardized form was a major step in the building of the 
algorithm. Indeed, hematologists found a certain amount of 
miscoding of hematological diagnoses for hospital stays. For 
example, for a given patient, some hospital discharges were 
coded CML while it was obvious that the patient suffered 
from Chronic MyeloMonocytic Leukemia (CMML), another 
hematological malignancy, given the sequence of care of the 
patients (treatments, other hospital discharge coded CMML, 
prognosis…). For that reason, we based our algorithm on the 
reimbursement of TKIs rather than on hospitalizations with a 
CML diagnosis code.
To our knowledge, the rare previous studies on CML 
using healthcare administrative databases29-31 chose TKI re-
imbursement combined with claims associated with diagno-
sis for CML (ICD‐9 code: 205.1) to analyze patterns of TKI 
treatment and healthcare resources consumption without an 
attempt to quantify prevalence.
Our work has several strengths. Firstly, our algorithm 
was validated internally by two expert hematologists and 
externally by comparison with the number of incident CML 
patients recorded in 18 French population‐based cancer reg-
istries in the same geographical areas. Secondly, our esti-
mate of CML prevalence is based on individual data at the 
nationwide level. It also provides estimates of CML preva-
lence in different geographical areas across France using an 
identical method of measurement. It can allow comparisons 
and improve health policy decision‐making. Finally, our al-
gorithm could be used to reestimate the CML prevalence rate 
in France periodically. The algorithm could also be used or 
adapted in other countries to identify CML patients, provided 
those countries have databases containing reimbursement/
dispensation of drugs data linked with medical discharge di-
agnosis databases.
Our study also has limitations. The first limitation was the 
frequent miscoding of hematological diagnoses for hospital 
stays, which explains why we based our algorithm on the re-
imbursement of TKIs rather than on hospitalizations with a 
CML diagnosis code. Hence, the algorithm is unable to iden-
tify three categories of true CML patients: (a) patients who 
have always been treated by interferon alone, (b) patients who 
have always received TKI in a clinical trial setting, the TKI 
being provided by the sponsor and thus not reimbursed by the 
National Health Insurance and (c) elderly patients who have 
been treated by cytoreductive chemotherapy only. The pro-
portion of patients treated by interferon alone was estimated 
at 0.7% in a cross‐sectional study on the management of first 
line CML patients in 2013 in France.32 Regarding the patients 
who received TKIs in the setting of clinical trials, searching 
the EU Clinical Trials Register, we found 25 clinical trials 
starting between 2004 and 2014 in France in CML patients. 
Excluding trials in which the patients had to be previously 
treated by TKI to be included in the trial, we estimated an 
upper range of 628 patients that could have been missed by 
the algorithm. Among those patients, several discontinued 
the trials and were thus identifiable by the algorithm if treated 
by a TKI outside the trial. In our internal validation, we iden-
tified three patients out of 100 who had not received TKI 
but were considered by the hematologists as possible CML 
patients given their whole sequences of care. These patients 
could correspond to the three different mentioned situations. 
Therefore, the impact of these limitations on the estimation 
of CML prevalence should be limited.
Secondly, we were unable to validate CML patients 
identified with our algorithm using medical records be-
cause data from the French national health insurance da-
tabases for research are anonymous. This difficulty was 
partially overcome through internal and external valida-
tions. However, for the same reason of anonymity, we 
were unable to perform an individual matching with the 
registries but we were able to compare total numbers of 
incident cases between the two sources of data. The algo-
rithm slightly overestimated the number of incident CML 
patients (from 14% in 2012 to 8% in 2014). Non‐CML 
patients receiving TKI for others diseases than the differ-
ential diagnoses already excluded by the algorithm may 
lead to this slight overestimation. As a sensitivity analy-
sis, we provided adjusted CML prevalence estimates tak-
ing into account this possible overestimation. Lastly, the 
algorithm depends on the care pathway of CML in general 
and more specifically on the indications of prescription of 
TKI at the time when we built the algorithm. In the future, 
some patients in deep molecular remissions may opt for a 
controlled discontinuation of TKI therapy. They will no 
longer be treated (and thus identifiable) by TKI. However, 
before entering into a treatment discontinuation strategy, 
patients must be treated by TKI for at least 5 years33 and 
are therefore identifiable by their TKI intake during this 
period. To continue to use the algorithm in the coming 
years, the observation period should be extended as much 
as possible and start before 2007, year of beginning of 
inclusion in the first French clinical trial (STIM1) as-
sessing controlled discontinuation of TKI therapy. If new 
TKIs were to be commercialized, the algorithm should be 
adapted to take into account this change, by adding new 
drugs in the list of TKIs.
In conclusion, we built and validated an algorithm to iden-
tify CML patients in healthcare administrative databases. We 
estimated the crude CML prevalence in France at 16.3 per 
100 000 inhabitants in 2014, using an innovative methodol-
ogy based on data from the French national health insurance 
databases. The algorithm could enable periodical re‐esti-
mation of the CML prevalence rate in France and could be 
implemented in other countries using healthcare claims data-
bases. The algorithm will also offer the opportunity to study 
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healthcare pathways and healthcare uses of French CML 
patients or to study the association between adverse events 
and CML treatments in the French national health insurance 
databases.
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